Helus Pharma, a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), has appointed Ken Kramer as Senior Vice President, Medical Affairs, effective immediately.
Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programmes, including global launch readiness, evidence generation and engagement with key opinion leaders. Most recently, he served as Vice President and Head of Medical Neuroscience at Bristol Myers Squibb, where he led an integrated medical strategy team to successfully launch the first new treatment for schizophrenia in over seven decades.
Michael Cola, CEO of Helus Pharma, said: “Ken brings both deep experience and an execution mindset to help us scale medical capabilities and advance our pipeline.”
At Karuna Therapeutics, as VP and Head of Medical Affairs, Kramer built and expanded medical capabilities during a period of significant organisational growth and supported the organisation through its acquisition. Earlier in his career, Kramer spent more than a decade leading US psychiatry medical affairs teams at AbbVie and its predecessor organisations, contributing to multiple successful product launches. He began his career in academic medicine as an Assistant Professor of Psychiatry.
Kramer commented: “Throughout my career in psychiatry, I’ve been driven by the profound unmet needs of patients and families affected by serious mental health conditions. Helus is driving innovation in its field through the strength of its science and its commitment to advancing NSAs as a differentiated approach to treating complex neuropsychiatric disorders.”